- ￥1900 - 5000
- 齐源
- 135209
- 国产/进口
- 2025年07月16日
- FC
- 大鼠
- 小鼠
6 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
齐源
- 库存：
999
- 靶点：
CD279 (PD-1)
- 级别：
CD279 (PD-1) Antibody
- 目录编号：
CD279 (PD-1) Antibody
- 克隆性：
单克隆
- 抗原来源：
大鼠
- 保质期：
CD279 (PD-1) Antibody
- 抗体英文名：
anti-mouse CD279 (PD-1) Antibody-APC
- 抗体名：
CD279 (PD-1) Antibody
- 标记物：
APC
- 宿主：
大鼠
- 适应物种：
小鼠
- 免疫原：
CD279 (PD-1) Antibody
- 亚型：
CD279 (PD-1) Antibody
- 形态：
CD279 (PD-1) Antibody
- 应用范围：
FC
- 保存条件：
2-8℃
- 浓度：
0.2 mg/ml
- 规格：
25 µg/ 100 µg
| 规格： | 25 µg | 产品价格： | ￥1900.0 |
|---|---|---|---|
| 规格： | 100 µg | 产品价格： | ￥5000.0 |
anti-mouse CD279 (PD-1) Antibody-APC详细如下：
Description ：CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging tothe CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells andthymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyteclonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positiveselection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation isessential for prolonged survival of intratesticular islet allografts.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Rat
Immunogen ：PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation ：The antibody was purified by affinity chromatography, and conjugated with APC under optimalconditions.
Concentration ：0.2 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C, and protected fromprolonged exposure to light. Do not freeze.
Application ：FC - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cellsin 100 µl volume. It is recommended that the reagent be titrated for optimal performance for eachapplication.
Excitation Laser ：Red Laser (633 nm)
Description ：CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging tothe CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells andthymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyteclonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positiveselection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation isessential for prolonged survival of intratesticular islet allografts.
Verified Reactivity ：Mouse
Antibody Type ：Monoclonal
Host Species ：Rat
Immunogen ：PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation ：Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation ：The antibody was purified by affinity chromatography, and conjugated with APC under optimalconditions.
Concentration ：0.2 mg/ml
Storage & Handling ：The antibody solution should be stored undiluted between 2°C and 8°C, and protected fromprolonged exposure to light. Do not freeze.
Application ：FC - Quality tested
Recommended Usage ：Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometricanalysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cellsin 100 µl volume. It is recommended that the reagent be titrated for optimal performance for eachapplication.
Excitation Laser ：Red Laser (633 nm)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
Application References(PubMed link indicatesBioLegend citation)：
1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
5. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations：
1. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
2. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
3. Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed
4. Zhou J, et al. 2019. Immunity. 50:403. PubMed
5. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
6. Wu Q, et al. 2021. Cancer Commun (Lond). Online ahead of prin. PubMed
7. Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed
8. Wang J, et al. 2019. Front Immunol. 9:3157. PubMed
9. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
10. Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed
11. Smith T, et al. 2014. J Immunol. 193:3409. PubMed
12. Almshayakhchi R, et al. 2021. Front Oncol. 11:636977. PubMed
1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
5. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations：
1. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
2. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
3. Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed
4. Zhou J, et al. 2019. Immunity. 50:403. PubMed
5. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
6. Wu Q, et al. 2021. Cancer Commun (Lond). Online ahead of prin. PubMed
7. Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed
8. Wang J, et al. 2019. Front Immunol. 9:3157. PubMed
9. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
10. Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed
11. Smith T, et al. 2014. J Immunol. 193:3409. PubMed
12. Almshayakhchi R, et al. 2021. Front Oncol. 11:636977. PubMed
文献支持
抗小鼠 CD279 (PD-1) 荧光标记APC 抗体
￥1900 - 5000
